U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H22N4O
Molecular Weight 298.3828
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MINAPRINE

SMILES

CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3

InChI

InChIKey=LDMWSLGGVTVJPG-UHFFFAOYSA-N
InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)

HIDE SMILES / InChI

Molecular Formula C17H22N4O
Molecular Weight 298.3828
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Minaprine, a psychotropic drug, which was effective in the treatment of various depressive states. This drug was withdrawn because of the serious side effect. It was found, that minaprine inhibited the following enzymes, acetylcholinesterase and monoamine oxidase (MOA) A. It also binds to dopamine D1 and D2 receptors. Experiments on rodents also have revealed that minaprine suppressed the inhibitory effect of hydroxytryptamine (5-HT) on dopamine (DA) release via the inhibition of 5-HT binding at the 5-HT2 receptor on the nerve terminal.

Approval Year

PubMed

PubMed

TitleDatePubMed
Pharmacological evaluation of minaprine dihydrochloride, a new psychotropic drug.
1982
Toxic cocaine- and convulsant-induced modification of forced swimming behaviors and their interaction with ethanol: comparison with immobilization stress.
2002 Nov 9
Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6.
2003 Dec 1
3-Benzidino-6(4-chlorophenyl) pyridazine blocks delayed rectifier and transient outward potassium current in acutely isolated rat hippocampal pyramidal neurons.
2006 Jul 10
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
2007 Sep 4
Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database.
2009 Nov

Sample Use Guides

minaprine 100 mg, 200 mg or 300 mg day-1 . The drug was administered for 6 weeks
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:14:16 UTC 2023
Edited
by admin
on Wed Jul 05 23:14:16 UTC 2023
Record UNII
00U7GX0NLM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MINAPRINE
INN   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
minaprine [INN]
Common Name English
MINAPRINE [MI]
Common Name English
AGR-1240
Code English
Minaprine [WHO-DD]
Common Name English
4-MORPHOLINEETHANAMINE, N-(4-METHYL-6-PHENYL-3-PYRIDAZINYL)-
Systematic Name English
MINAPRINE [USAN]
Common Name English
4-[2-[(4-Methyl-6-phenyl-3-pyridazinyl)amino]ethyl]morpholine
Systematic Name English
CB-30038
Code English
CANTOR
Brand Name English
Classification Tree Code System Code
WHO-ATC N06AX07
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
WHO-VATC QN06AX07
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
NCI_THESAURUS C265
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C66158
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
PUBCHEM
4199
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
ChEMBL
CHEMBL278819
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
CAS
25905-77-5
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
WIKIPEDIA
MINAPRINE
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
DRUG CENTRAL
1812
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
RXCUI
30031
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY RxNorm
DRUG BANK
DB00805
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
MERCK INDEX
M7551
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
247-329-8
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
CHEBI
51038
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
SMS_ID
100000080638
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
INN
3503
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
FDA UNII
00U7GX0NLM
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
EPA CompTox
DTXSID5048477
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
EVMPD
SUB08974MIG
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
MESH
C006149
Created by admin on Wed Jul 05 23:14:16 UTC 2023 , Edited by admin on Wed Jul 05 23:14:16 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY